Ennaid Therapeutics | Newsweek’s Disruptive Women
post-template-default,single,single-post,postid-1,single-format-standard,ajax_fade,page_not_loaded,,qode-theme-ver-7.7,wpb-js-composer js-comp-ver-6.6.0,vc_non_responsive

Newsweek’s Disruptive Women

24 May Newsweek’s Disruptive Women

Darnisha tops Newsweek’s list of entrepreneurs you can bet on


As many as 400 million people are infected with the potentially deadly dengue virus each year. Right now, there are no vaccines, and the only means of prevention is to avoid exposure to mosquitoes. But what if dengue could be cured? Ennaid Therapeutics has exclusive, worldwide rights to develop and commercialize what Harrison is confident will be the first cure for dengue. Her company licensed a flavivirus inhibitor technology that she says has been shown to inhibit more than 99 percent of mosquito-borne viruses such as dengue virus. Harrison has raised seed capital, and her five-person team is now raising $20 million more to complete testing and bring the potential cure to market.

View Article



No Comments

Sorry, the comment form is closed at this time.